221results about How to "Reduce infarct size" patented technology

An apparatus for providing electromagnetic biostimulation of tissue includes a source of electromagnetic radiation and relay optics operatively connected to the source of electromagnetic radiation for transmitting electromagnetic radiation for biostimulating tissue. An echo imaging device for producing an ultrasonic image of the tissue is also provided. And, control circuitry is used for controlling the electromagnetic radiation.

Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin are disclosed. In particular, the invention relates to formulations comprising apelin encapsulated in liposome nanocarriers conjugated with polyethylene glycol (PEG) and their use in treatment of cardiovascular and pulmonary diseases and disorders. Encapsulation of apelin in PEG-conjugated liposomes significantly enhances efficacy, improves cellular uptake of apelin, and allows for sustained and extended release of apelin under physiological conditions.

A system and method in accordance with the present invention provides a infusion catheter that is flexible, has such a smooth traction and a low profile to minimize break up of the obstruction when crossing it, can access distal vasculature quickly, is easy to use and readily to be implemented in the conventional PCI. Another object is to provide a method that can be performed within a short period of time and employs the catheter described herein to infuse a therapeutic agent distally to the obstruction before it is removed as a means of reducing reperfusion injury, protecting distal vasculature and microcirculation, preserving myocytes, reducing infarct size and ischemic damages in the heart, brain, lung, liver, kidney and limb. Another object is to provide complementary feature options to the infusion catheter and the aspiration catheter to improve the speed and quality of the vessel clearance.

The invention relates to a high-performance high-density polyethylene (HDPE) pipe fitting which consists of functional master batches and an HDPE base material. A preparation method is characterized by comprising the following steps of: selecting raw materials, mixing the raw materials, feeding the raw materials under vacuum, drying the raw materials, extruding the raw materials by an inner layer extruder, extruding the raw materials by an outer layer extruder, fixing the diameter by a diameter fixing sleeve, spraying a vacuum sizing box, spraying a cooling water tank, spraying codes by a code sprayer, conveying a product by a caterpillar-tractor, packaging finished products, and detecting the specifications of the HDPE pipe fittings. The HDPE pipe fitting can be produced by using existing equipment and a production technology; the additional value of the products can be increased; the HDPE pipe fitting can be widely applied.

The invention relates to application of an edaravone and borneol medicinal composition to preparation of a medicament for preventing and/or treating myocardial ischemia-reperfusion injury.

A method is provided for reducing hypertension and/or heart failure in a mammal. Preferably, the method is used to treat or prevent tissue damage to a human heart. The method includes administering an effective amount of a Jak2 inhibitor, preferably a tyrphostin, such as AG490.

The invention belongs to the medication technical field, which discloses the medicine and the preparation method for treating the coronary heart disease and miocardial infarction. The medicine is mainly prepared from ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali and Chinese angelica, or ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali, Chinese angelica, cassia twig and liquorice, or ginseng root, dwarf lilyturf tuber, Chinese magnoliavine fruit, radix astragali, Chinese angelica, cassia twig, liquorice, danshen root, red peony root, radix notoginseng and safflower, according to certain ratios of weights. The invention can be made to any type of medicament that can be accepted by the clinic or pharmacology, which is the good quality oral preparation. The medicine has effects of Qi-replenishing, Yin-nourishing and pulse-invigorating and blood circulation activating to dissipate blood stasis and lipid lowing, which can be used to curing the chest distress, hard breathe, heart-throb, angina and arrhythmia caused by coronary heart disease and miocardial infarction, the recovery period of the cerebral thrombosis and the sequelae of the cerebral thrombosis, the effects are obvious.

The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A₂, and even more particularly phospholipase A₂ derived from the snake venom of Naja sputatrix

A Chinese medicine in the form of dropping pills for treating cardiovascular and cerebrovascular diseases is prepared from ginseng and ophiopogon root. Its advantage is high contents of ginsenoside and ophiopogon saponin.

The invention provides a new matter glycine-L-cysteine-homotaurine tripeptide and an application of the glycine-L-cysteine-homotaurine tripeptide in the preparation of medicines for treating cerebral apoplexy. The anti-cerebral apoplexy medicines prepared by glycine-L-cysteine-homotaurine tripeptide products have better curative effect. The animal experiment shows that the glycine-L-cysteine-homotaurine tripeptide can improve the behaviors of rats and has the effect on cerebral apoplexy treatment. The effect of the tripeptide is obviously superior to the same dose of homotaurine, taurine and other compounds reported by existing literatures or traditional medicines for clinical use.

The invention discloses miR-106b-5p, a detection primer thereof and application of the antisense nucleotide sequence thereof in the fields of ischemic cerebral stroke diagnosis and treatment, and belongs to the field of application of micro ribonucleic acid. The sequence of a reverse transcription primer in the detection primer of the miR-106b-5p is 5'-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGATCTGCAC-3'. The antisense nucleotide sequence of the miR-106b-5p is 5'-AUCUGCACUGUCAGCACUUUA-3'. The miR-106b-5p, the detection primer thereof and the antisense nucleotide sequence thereof are associated with acute ischemic cerebral strokes, the miR-106b-5p can become an auxiliary index of acute ischemic cerebral stroke clinical detection, and a therapeutic target is provided for prevention of the disease. The miR-106b-5p has the advantages of being good in treatment effect, easy to operate, free of toxic and side effects and the like.

A method is provided for the prevention of ischemia/reperfusion injury, for example, in patients undergoing heart surgery, and involves the administration of a phosphodiesterase-5 (PDE-5) inhibitor such as sildenafil. The method may also be used during or after a heart attack to prevent or lessen ischemic heart damage.

The invention relates to a drug compound used to treat ischemia cerebrovascular disease, which is formed by panaxoside and bilobalide, wherein, the invention can significantly reduce the infarct size of brain to treat the ischemia condition, cerebral thrombus or the like.

The present invention relates to a medicine composition for curing angiocardiopathy and cerebrovascular disease. Said medicine composition contains ginsenoside and breviscapine.

The invention provides a medicine composition used for treating cardio-cerebrovascular and a preparing method thereof in order to overcome the defects of large dosage and indefinite mechanism of effective components of the existing Chinese medicine preparation used for treating the cardio-cerebrovascular. The medicine composition is made of medicine materials comprising the monomer compositions of ginsenoside and astragalus saponin and excipient and is prepared by conventional preparation technology. Compared with prior art, the medicine composition of the invention has definite components, reliable curative effect, small dosage and manageable quality, so the medicine composition can effectively treat the cardio-cerebrovascular.

The present invention provides compositions and methods for increasing proliferation, increasing cell cycle activity, and/or proliferation of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to slow, reduce, or prevent the onset of cardiac damage caused by, for example, myocardial ischemia, hypoxia, stroke, or myocardial infarction in vivo. In addition, the methods and compositions of the invention can be used to enhance proliferation of differentiated cardiomyocytes in vitro and/or ex vivo, which can then be used in tissue grafting.

The invention provides a Chinese compound preparation for treating a coronary heart disease and a preparation method thereof. The preparation of the Chinese compound preparation for treating the coronary heart disease comprises the following steps of: (1) extracting root of red-rooted salvia by using ethanol, filtering the extracting solution and concentrating the filtrate to be clear plaster with the relative density of 1.01 at the temperature of between 55 and 60 DEG C; (2) decocting dregs of the root of red-rooted salvia with water, filtering, and concentrating the filtrate to be clear plaster with the relative density of 1.15 to 1.17 at the temperature of 60 DEG C; (3) extracting pseudo-ginseng by using aqueous solution of ethanol in a volume ratio of ethanol to water of 65 percent, filtering the extracting solution and concentrating the filtrate to be clear plaster with the relative density of 1.05 to 1.08; and (4) mixing the three kinds of clear plaster and borneol, wherein the weight ratio of the root of red-rooted salvia to the pseudo-ginseng to the borneol is 650-700:200-230:8-15. Clinical test show that: the Chinese compound preparation prepared by the preparation method has the extract curative effect of treating the coronary heart disease and angina pectoris (a qi stagnation and blood stasis disease) and no toxic or side effect caused by the medicament in the clinical tests, is safe and effective for treating the coronary heart disease and angina pectoris (the qi stagnation and blood stasis disease), and has better curative effect than that of compound salvia tablets.

The invention provides techniques for producing a saline slush for induction of therapeutic hypothermia. Embodiments of the invention provide a gain of hypothermic therapies over the use of chilled saline alone.

The invention discloses application of an emodin succinyl ester compound in preparation of a medicine for resisting myocardial ischemia and belongs to the technical field of medicines. The emodin succinyl ester compound has a structure shown as a formula I (R is C1 to C5 alkyl). Pharmacological experiments on rats and mice for experimenting myocardial infarction prove that the emodin succinyl ester compound has the advantages of remarkable myocardial ischemia resisting effect, good safety, simplicity and convenience for drug utilization, low raw material price and easiness for obtaining, and convenience for transportation and preservation. The emodin succinyl ester compound disclosed by the invention is used as a myocardial ischemia resisting drug and has a wide application prospect. The formula I is shown in the description.

The invention belongs to the medical technical field and discloses a drug combination used for the cardio-cerebrovascular disease. The drug combination contains the pharmacodynamic components of the raw materials of the drugs of snakegourd or snakegourd extract and hawthorn leaves or hawthorn leaf extract. The invention also discloses preparations, which contain the drug combination and the preparation method of the preparations. The drug combination can be made into the preparation type, which is acceptable in the clinic or the pharmacy, and the injection preparation and the oral preparation are preferential. The drug combination is mainly used for remedying the cardio-cerebrovascular diseases of the coronary heart disease, the angina, the miocardial infarction, the blood stasis type corpulmonale, the ischemic encephalopathy, the cerebral thrombosis, the hypertension, the hyperlipemia etc. The drug combination of the invention has the synergistic interaction. Compared with simply using the snakegourd or the snakegourd extract and the hawthorn leaves or the hawthorn leaf extract, the effect is improved greatly, and the invention is provided with low toxicity, high safety and good stability.

The invention relates to a health soup for curing myocardial infarction, which consists of the main components of 10-15 grams of dried raw ginseng, 2 grams of radix scutellariae, 15 grams of raw radix astragali, 15 grams of radix salviae miltiorrhizae, 10 grams of radix angelicae sinensis, 10 grams of corydalis tuber, 5 grams of radix sophorae falvescentis, 10 grams of hemlock parsley vines, 5 grams of climbing nightshade, 12 grams of patchouli, 10 grams of Eupatorium fortunei Turcz., 10 grams of dried orange peel, 10 grams of tuber pinellia, 6-10 grams of rhubarb and other Chinese traditional medicines. A preparation method comprises the following steps: putting the herbal medicines into a pottery jar, adding water for soaking for 20 minutes, decocting for 15 minutes with mild fires, and taking 250 grams of liquid medicine for administration twice per day; the dosages in the prescription are all natural Chinese herbal medicines, the medicinal properties of the Chinese herbal medicines are reserved, and the health soup has the functions of improving the vitality of myocardial cells, improving the microcirculation of cardiac muscles, restoring the damaged cardiac muscles, and reducing infarct sizes.

The invention relates to a thymus plant extract or composition and application thereof. The preparation method comprises the following steps: firstly quenching active pharmaceutical ingredients with acetone; performing acidification by use of H2SO4 with certain concentration; extracting the extracting solution with ethyl acetate for 2-3 times, thereby obtaining a thymus plant extract containing carvacrol, tanshinol, scutellarein, scutellarin, 5,4'-dyhydroxyl-6,7,8-trimethoxy flavone, oleanolic acid and rosmarinic acid. The thymus plant also provides a traditional Chinese medicine composition for treating cardiovascular and cerebrovascular disease. The traditional Chinese medicine composition is prepared from the following active pharmaceutical ingredients in parts by weight: 200-500 parts of thymus plant, 100-300 parts of curcuma roots, 100-300 parts of rhizoma sparganii, 200-400 parts of radix angelica sinensis, 100-200 parts of ginkgo leaves, 100-200 parts of licorice root, 200-400 parts of radix codonopsis pilosulae and 200-500 parts of rhizoma ligustici wallichii. The traditional Chinese medicine composition is rapid in medical effect taking and less in toxic and side effects, thereby being a favorable medicament for treating cardiovascular and cerebrovascular diseases.